Devices for Monitoring Heparin and Protamine in the Operating Room

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 7, Issue 4, 2003, Pages 379-385

  Santrach, Paula J ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PROTAMINE;

ACCREDITATION; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CORRELATION ANALYSIS; DEVICE; DRUG ANTAGONISM; DRUG MEGADOSE; HUMAN; INSTRUMENTATION; OPERATING ROOM; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT MONITORING; REGULATORY MECHANISM; REVIEW; STANDARD; THORAX SURGERY; THROMBOSIS; VASCULAR SURGERY;

EID: 1242306880     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925320300700403     Document Type: Review

References (29)

1. Hattersley PG: Activated coagulation time of whole blood. JAMA 196:436-440, 1966.
2. Bull BS, Korpman RA, Huse WM, et al: Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 69:674-684, 1975.
3. Bull BS, Huse WM, Brauer FS, et al: Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 69:685-689, 1975.
4. Murray DJ, Brosnahan WJ, Pennell B, et al: Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11:24-28, 1997.
5. Andrew M, MacIntrye B, MacMillan J, et al: Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thrombos Haemostas 70:937-941, 1993.
6. Carter AJ, Hicks K, Heldman AW, et al: Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques. Cathet Cardiovasc Diag 39:97-102, 1996.
7. Helft G, Choktron S, Beygui F, et al: Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 45:329-331, 1998.
8. Horkay F, Martin P, Rajah SM, et al: Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg 53:822-826, 1992.
9. Leyvi G, Shore-Lesserson L, Harrington D, et al: An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation. Anesth Analg 92:578-583, 2001.
10. Mulry C, Le Veen R, Sobel M, et al: Assessment of heparin anticoagulation during peripheral angioplasty. J Vasc Interv Radiol 2:133-139, 1991.
11. Dougherty K, Gaos C, Bush H, et al: Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 26:260-263, 1992.
12. Despotis GJ, Levine V, Joist JH, et al: Antithrombin III during cardiac surgery: Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 85:498-506, 1997.
13. Despotis G, Summerfield AL, Joist HJ, et al: Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108:1076-1082, 1994.
14. Huyzen RJ, van Oeveren W, Wei F, et al: In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Ann Thorac Surg 62:533-537, 1996.
15. Despotis GJ, Filos KS, Levine V, et al: Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 82:1126-1131, 1996.
16. Dietrich W, Dilthey G, Spannagl M, et al: Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 83:679-689, 1995.
17. Feindt P, Seyfert UT, Volkmer I, et al: Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surgeon 42:218-221, 1994.
18. Ducart AR, Collard EL, Osselaer JC, et al: Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothorac Vasc Anesth 11:878-879, 1997.
19. Hogan WJ, McBane RD, Santrach PJ, et al: Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc 75:971-976, 2000.
20. Koster A, Hansen R, Grauhan O, et al: Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. J Cardiothorac Vasc Anesth 14:249-252, 2000.
21. Nuttall GA, Oliver WC, Santrach PJ, et al: Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: A prospective observational case series. Anesth Analg 96:344-350, 2003.
22. Hezard N, Metz D, Potron G, et al: Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors. Thomb Haemost 80:865-866, 1998.
23. Hardy JF, Belisle S, Robitaille D, et al: Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 112:154-161, 1996.
24. Despotis GJ, Joist JH, Goodnough LT, et al: Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 113:611-613, 1997.
25. Schlueter AJ, Pennell BJ, Olson JD: Evaluation of a new protamine titration method to assay heparin in whole blood and plasma. Am J Clin Pathol 107:511-520, 1997.
26. Codispoti M, Ludlam CA, Simpson D, et al: Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 71:922-928, 2001.
27. Despotis GJ, Joist HJ, Hogue CW Jr, et al: The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 110:46-54, 1995.
28. Despotis GJ, Joist HJ, Hogue CW Jr, et al: More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 76:902-908, 1996.
29. Jobes DR, Aitken GL, Shaffer GW: Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 110:36-45, 1995.